Merit Medical Launches the basixALPHA™ Inflation Device

Rhea-AI Summary

Merit Medical Systems has launched the basixALPHA™ Inflation Device for angioplasty procedures, aiming to enhance efficiency and ease of use. This ergonomic device allows for one-handed preparation and fast inflation, crucial for opening blocked arteries and enhancing blood flow to the heart. With over 10 million procedures completed using Merit’s inflation devices, this innovation continues the company's leadership in healthcare technology. The basixALPHA is part of a robust portfolio supporting the annual 1.2 million coronary angioplasties conducted in the U.S.

Positive

• Launch of basixALPHA™ Inflation Device enhances procedural efficiency.
• Ergonomic design allows for one-handed operation, improving user experience.
• Strong market position with over 10 million procedures using Merit devices.
• Continues to support the annual 1.2 million coronary angioplasties in the U.S.

Negative

• None.

Ergonomic device provides fast inflation to streamline angioplasty procedures

SOUTH JORDAN, Utah, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the basixALPHA™ Inflation Device.

The basixALPHA is the latest addition to the Merit inflation device portfolio. Products include analog and digital devices with low- and high-pressure capacity for inflation, deflation, and measurement of pressures in angioplasty balloons. Merit’s commitment to excellence in inflation device technology has resulted in decades of industry leadership. More than 10 million procedures have been completed using Merit inflation devices worldwide.

The new ergonomic device is designed for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures. Angioplasty, a type of percutaneous coronary intervention (PCI), is used to open narrowed or blocked arteries. Opening blocked arteries facilitates blood flow to the heart, minimizing damage. More than 1.2 million coronary angioplasty procedures are performed each year within the US.¹

Learn more about the basixALPHA Inflation Device

“As a leader in inflation device technology, Merit understands that inflation devices serve as staples in the cath lab,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “To provide physicians with an improved device, we listened to their feedback and innovated the basixALPHA—a technology that delivers fast inflation when needed most. It fits well within our robust portfolio of inventive yet reliable inflation device technologies, helping to improve the physician experience and patient outcomes around the globe.”

^{1. Medical News Today. 2019. “What to Know About Angioplasty.” https://www.medicalnewstoday.com/articles/327154}

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS

PR/Media Inquiries 
Sarah Comstock 
Merit Medical 
+1-801-432-2864 | sarah.comstock@merit.com

INVESTOR INQUIRIES 
Mike Piccinino, CFA, IRC 
Westwicke - ICR 
+1-443-213-0509 | mike.piccinino@westwicke.com 

FAQ

What is the basixALPHA Inflation Device from Merit Medical Systems?

The basixALPHA Inflation Device is a newly launched ergonomic device designed for angioplasty procedures, enabling fast inflation with minimal exertion.

When was the basixALPHA Inflation Device released in the U.S.?

The basixALPHA Inflation Device was commercially released in the U.S. on November 28, 2022.

What are the benefits of the basixALPHA Inflation Device?

The device allows for one-handed preparation and fast inflation, which can streamline angioplasty procedures and improve patient outcomes.

How many coronary angioplasties occur annually in the U.S.?

More than 1.2 million coronary angioplasty procedures are performed each year in the United States.

What company produces the basixALPHA Inflation Device?

The basixALPHA Inflation Device is manufactured by Merit Medical Systems, which specializes in healthcare technology.